Quality control in tissue engineering

The rapid development in the multidisciplinary field of tissue engineering has resulted in a variety of new and innovative medicinal products, often carrying living cells, intended to repair, regenerate or replace damaged human tissue.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

The rapid development in the multidisciplinary field of tissue engineering has resulted in a variety of new and innovative medicinal products, often carrying living cells, intended to repair, regenerate or replace damaged human tissue. Tissue engineered medicinal products (TEMPs) vary in terms of the type and origin of cells and the product’s complexity.

As all medicinal products, the safety and efficacy of TEMPs must be consistent throughout the manufacturing process. Quality control and assurance are of paramount importance and products are constantly assessed throughout the manufacturing process to ensure their safety, efficacy, consistency and reproducibility between batches.

The European Medicines Agency (EMA) is responsible for the development, assessment and supervision of medicines in the EU. The appointed committees are involved in referral procedures concerning safety or the balance of benefit/risk of a medicinal product.

In addition, the committees organize inspections with regards to the conditions under which medicinal products are being manufactured. For example, the compliance with good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) and pharmacovigilance (PhV).

Quality considerations

Careful and detailed documentation concerning the characteristics of the starting materials (e.g. history of the cell line derivation and cell banking) and manufacturing process steps (e.g. procurement of tissue or cells and manipulation) must be maintained. The cellular part of every cell-based medicinal product must be characterized in terms of identity, purity, potency, viability and suitability for the intended use.

The non-cellular constituents must be also characterized with regards to their intended function in the final product. For example, scaffolds or membranes that are used to support the cells must be identified and characterized in terms of porosity, density, microscopic structure and particular size.

The same requirement for characterization applies for biologically active molecules, such as growth factors or cytokines.

Release specifications

Proper quality control involves the release testing of the final product through updated and validated methods. The release specifications of the product must be selected on the basis of the parameters defined during the characterization studies and the appropriate release tests must be performed.

In case a release test cannot be performed on the final product but only on previous stages of the manufacturing, exceptions can be made after proper justification. However, in these cases adequate quality control has to rise from the manufacturing process.

Specifications about the stability of the product, the presence or not of genetically modified cells, structural components and whether it is a combination product must also be defined.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1345590013 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001345590013 · captured 2026-03-26 · not yet sealed in the ledger · verify the chain · version history

Cite this page as: encyclopegia.org, “Quality control in tissue engineering”, snapshot enwiki-001345590013. https://encyclopegia.org/a/quality-control-in-tissue-engineering

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.